Population heterogeneity in Plasmodium vivax relapse risk

Eva Stadler, Deborah Cromer, Somya Mehra, Adeshina I. Adekunle, Jennifer A. Flegg, Nicholas M. Anstey, James A. Watson, Cindy S. Chu, Ivo Mueller, Leanne J. Robinson, Timothy E. Schlub, Miles P. Davenport, David S. Khoury

Research output: Contribution to journalArticlepeer-review

60 Downloads (Pure)


A key characteristic of Plasmodium vivax parasites is their ability to adopt a latent liver-stage form called hypnozoites, able to cause relapse of infection months or years after a primary infection. Relapses of infection through hypnozoite activation are a major contributor to blood-stage infections in P. vivax endemic regions and are thought to be influenced by factors such as febrile infections which may cause temporary changes in hypnozoite activation leading to 'temporal heterogeneity' in reactivation risk. In addition, immunity and variation in exposure to infection may be longer-term characteristics of individuals that lead to 'population heterogeneity' in hypnozoite activation. We analyze data on risk of P. vivax in two previously published data sets from Papua New Guinea and the Thailand-Myanmar border region. Modeling different mechanisms of reactivation risk, we find strong evidence for population heterogeneity, with 30% of patients having almost 70% of all P. vivax infections. Model fitting and data analysis indicates that individual variation in relapse risk is a primary source of heterogeneity of P. vivax risk of recurrences. Trial Registration: ClinicalTrials.gov NCT01640574, NCT01074905, NCT02143934.

Original languageEnglish
Article numbere0010990
JournalPLoS Neglected Tropical Diseases
Issue number12
Publication statusPublished - 1 Dec 2022


Dive into the research topics of 'Population heterogeneity in Plasmodium vivax relapse risk'. Together they form a unique fingerprint.

Cite this